TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7/31/25 16:05 | 7/30/25 | CRDF | Cardiff Oncology, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Pace Gary W | CA | D | P | 711 | 2.45 | 0 | 290 | 12 | 2,676 | M | |||||||||||||||
12/12/24 16:05 | 12/11/24 | CRDF | Cardiff Oncology, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Pace Gary W | CA | D | P | 940 | 2.60 | 0 | 362 | 21 | 2,107 | M | |||||||||||||||
3/8/24 17:33 | 3/6/24 | PCRX | Pacira Biosciences, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Pace Gary W | FL | D | S.m | -3,656 | 30.64 | 0 | -119 | -84 | 22 | D | |||||||||||||||
12/19/23 18:39 | 12/19/23 | CRDF | Cardiff Oncology, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Pace Gary W | CA | D | P | 41 | 1.37 | 0 | 30 | 4 | 698 | D | |||||||||||||||
5/15/23 18:53 | 5/11/23 | PCRX | Pacira Biosciences, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Pace Gary W | FL | D | M.d | 209 | 29.90 | 0 | 7 | 5 | 140 | D | |||||||||||||||
5/15/23 18:53 | 5/11/23 | PCRX | Pacira Biosciences, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Pace Gary W | FL | D | S.d | -210 | 41.78 | 0 | -5 | -3 | 140 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |